Compare EPC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | OLMA |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 949.3M |
| IPO Year | 1999 | 2020 |
| Metric | EPC | OLMA |
|---|---|---|
| Price | $26.64 | $9.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $23.33 | ★ $44.89 |
| AVG Volume (30 Days) | 464.7K | ★ 791.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,223,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.73 | $6.65 |
| 52 Week High | $29.95 | $36.26 |
| Indicator | EPC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 43.34 |
| Support Level | $25.78 | $9.89 |
| Resistance Level | $29.91 | $12.37 |
| Average True Range (ATR) | 0.98 | 0.52 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 18.34 | 36.69 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.